# Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

> **NCT02886884** · PHASE1,PHASE2 · COMPLETED · sponsor: **Joshua M Hare** · enrollment: 16 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** 20 million Allogeneic Mesenchymal Human Stem Cells
- **DRUG:** 100 million Allogeneic Mesenchymal Human Stem Cells

## Key facts

- **NCT ID:** NCT02886884
- **Lead sponsor:** Joshua M Hare
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2019-08-26
- **Final completion:** 2020-09-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02886884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02886884, "Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02886884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*